<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="3-part\PMC7036483\results\search\disease\results.xml">
  <result pre="in hundreds of thousands annually. Vaccines are used to prevent" exact="influenza" post="outbreaks, however, the influenza virus mutates and annual vaccination"/>
  <result pre="annually. Vaccines are used to prevent influenza outbreaks, however, the" exact="influenza" post="virus mutates and annual vaccination is required for optimal"/>
  <result pre="adaptation associated with egg-based vaccine production. This article reviews the" exact="influenza" post="vaccine development process and describes the implications of the"/>
  <result pre="Organization since the 2017 season. The traditional manufacturing process for" exact="influenza" post="vaccines relies on fertilized chicken eggs that are used"/>
  <result pre="vaccine effectiveness during a predominantly H3N2 season. During the 2017–2018" exact="influenza" post="season, a small number of studies conducted in the"/>
  <result pre="more effective than egg-based vaccines. Adoption of cell-culture technology for" exact="influenza" post="vaccine manufacturing has been reported to improve manufacturing efficiency"/>
  <result pre="Despite a well-established system of surveillance and vaccine production, current" exact="influenza" post="vaccines, even when given annually, do not provide complete"/>
  <result pre="eggs for vaccine bulk production. Background Influenza is an infectious" exact="respiratory disease" post="that has three different genera or types, A, B,"/>
  <result pre="B/Yamagata and B/Victoria (Figure 1).2,4 Figure 1. Anatomy of an" exact="influenza" post="virus. Influenza A is the most frequent cause of"/>
  <result pre="influenza virus. Influenza A is the most frequent cause of" exact="influenza" post="in humans.2 The A/H3N2 strain has the highest rate"/>
  <result pre="highest rate of morbidity and mortality. One analysis of 31" exact="influenza" post="seasons in the United States showed that in 22"/>
  <result pre="the United States showed that in 22 seasons in which" exact="influenza" post="A/H3N2 was the dominant strain mortality rates were 2.7"/>
  <result pre="winter of 2014–2015 in England, 28,484 deaths were due to" exact="influenza" post="with 93% occurring in persons 65 years or older.8 In"/>
  <result pre="93% occurring in persons 65 years or older.8 In the 2017" exact="influenza" post="season in Australia when H3N2 was estimated to make"/>
  <result pre="reported in a single nonpandemic season.10 The more genetically stable" exact="influenza" post="B viruses, B/Yamagata and B/Victoria, have been circulating for"/>
  <result pre="infections, and exacerbation of many chronic conditions such as asthma," exact="congestive heart failure," post="and chronic obstructive pulmonary disease.11 Most who are infected"/>
  <result pre="and chronic obstructive pulmonary disease.11 Most who are infected with" exact="influenza" post="experience mild illness that does not require medical intervention"/>
  <result pre="require medical intervention and resolves within 2 weeks; however, for others" exact="influenza" post="complications can require hospitalization and can lead to death.11"/>
  <result pre="death.11 In the United States, an analysis of 31 consecutive" exact="influenza" post="seasons (1976–2007) showed that the estimated average number of"/>
  <result pre="seasons (1976–2007) showed that the estimated average number of annual" exact="influenza" post="deaths due to pneumonia and influenza causes was 6309"/>
  <result pre="the estimated average number of annual influenza deaths due to" exact="pneumonia" post="and influenza causes was 6309 with a low of"/>
  <result pre="average number of annual influenza deaths due to pneumonia and" exact="influenza" post="causes was 6309 with a low of 961 in"/>
  <result pre="observed, an outbreak is considered an epidemic. When a new" exact="influenza" post="virus emerges due to antigenic shift, a pandemic can"/>
  <result pre="the outbreak and the groups most affected vary in each" exact="influenza" post="epidemic, certain high-risk groups have been identified who should"/>
  <result pre="treatment.2 In the United States, the recommendation is for annual" exact="influenza" post="vaccination of everyone 6 months and older with any licensed,"/>
  <result pre="vaccination of everyone 6 months and older with any licensed, age-appropriate" exact="influenza" post="vaccine.13 The World Health Organization (WHO) recommends influenza vaccination"/>
  <result pre="licensed, age-appropriate influenza vaccine.13 The World Health Organization (WHO) recommends" exact="influenza" post="vaccination for all high-risk groups (e.g. pregnant women at"/>
  <result pre="individuals with chronic medical conditions, and health-care workers).1 Technology for" exact="influenza" post="vaccine production Influenza vaccines are available in different forms:"/>
  <result pre="vaccine production Influenza vaccines are available in different forms: inactivated" exact="influenza" post="vaccines (IIV) and live attenuated influenza vaccines (LAIV). IIVs"/>
  <result pre="in different forms: inactivated influenza vaccines (IIV) and live attenuated" exact="influenza" post="vaccines (LAIV). IIVs are produced to protect against three"/>
  <result pre="are produced to protect against three (trivalent) or four (quadrivalent)" exact="influenza" post="viruses; whereas LAIVs are produced as quadrivalent only. IIVs"/>
  <result pre="less immunogenic in populations that have not been exposed to" exact="influenza" post="vaccines; in a seasonal setting, two doses of these"/>
  <result pre="that increase immune responses to an antigen—can be added to" exact="influenza" post="antigens to improve vaccine immunogenicity, particularly for vulnerable populations."/>
  <result pre="antigens to improve vaccine immunogenicity, particularly for vulnerable populations. An" exact="influenza" post="vaccine with MF59 adjuvant, which is a squalene oil-in-water"/>
  <result pre="its components.15 A number of adjuvants are used in pandemic" exact="influenza" post="vaccines including aluminum salt, MF59, and AS03.16 Other adjuvants"/>
  <result pre="immunostimulatory DNA sequences and bacterium-derived components.14 A key characteristic of" exact="influenza" post="virus is continuous antigenic drift which requires that the"/>
  <result pre="2). This need for annual reformulation is unique to the" exact="influenza" post="vaccines.17 Figure 2. Antigenic drift and antigenic shift in"/>
  <result pre="influenza vaccines.17 Figure 2. Antigenic drift and antigenic shift in" exact="influenza" post="vaccines. Antigenic drift occurs in all influenza types (A,"/>
  <result pre="antigenic shift in influenza vaccines. Antigenic drift occurs in all" exact="influenza" post="types (A, B, and C) and is caused by"/>
  <result pre="of hemagglutinin, neuraminidase, or both. Antigenic shift occurs only in" exact="influenza" post="type A and is caused by exchanges of whole"/>
  <result pre="specimens to WHO Collaborating Centers to identify the next year’s" exact="influenza" post="virus. A network of associated laboratories tests approximately 1"/>
  <result pre="1 million samples annually and provide thousands of samples of" exact="influenza" post="viruses to WHO for further evaluation. Twice each year,"/>
  <result pre="uncommon. Between 2002 and 2015, five virus mismatches to the" exact="influenza" post="vaccine had occurred.20 The potential effect of these mismatches"/>
  <result pre="(Figure 3). Figure 3. Visits for influenza-like illness during selected" exact="influenza" post="seasons. Influenza manufacturing processes The seed virus isolation and"/>
  <result pre="manufacturing processes The seed virus isolation and manufacturing process for" exact="influenza" post="vaccines can also directly affect the match of the"/>
  <result pre="vaccine virus to circulating strains and thereby the effectiveness of" exact="influenza" post="vaccines (Figure 4). Figure 4. Traditional egg-based and emerging"/>
  <result pre="Figure 4. Traditional egg-based and emerging cell-based manufacturing processes for" exact="influenza" post="vaccines compared. CVV, candidate vaccine viruses; MDCK, Madin–Darby Canine"/>
  <result pre="vaccine viruses; MDCK, Madin–Darby Canine Kidney. For more than 70 years," exact="influenza" post="vaccines have been manufactured through an egg-dependent process.4 Viruses"/>
  <result pre="and the key viral antigens are purified for use in" exact="influenza" post="vaccine.21,22 The traditional egg-based process is a time-tested process"/>
  <result pre="eggs depending on the whether it is TIV or quadrivalent" exact="influenza" post="vaccine (QIV), which means the coordination of the production"/>
  <result pre="do not grow well.23 Importantly, the manufacturing process for inactivated" exact="influenza" post="vaccines requires that the influenza virus infects the cells"/>
  <result pre="the manufacturing process for inactivated influenza vaccines requires that the" exact="influenza" post="virus infects the cells used in the process (e.g."/>
  <result pre="humans and thus naturally grow in some mammalian cells. The" exact="influenza" post="virus needs to bind to a cellular receptor in"/>
  <result pre="surface of mammalian cells. This means that for a human" exact="influenza" post="virus to grow well in avian cells it needs"/>
  <result pre="Unfortunately, the region in which the adaption occurs on the" exact="influenza" post="virus is the same region that is dominant antigenically."/>
  <result pre="drive egg-based vaccines to potentially be less effective at preventing" exact="influenza" post="infection than their nonegg adapted mammalian cell grown counterparts.24"/>
  <result pre="Food and Drug Administration (FDA) that uses cell-culture technology for" exact="influenza" post="vaccine production. In 2016 this process also extended to"/>
  <result pre="the 2017–2018 season, WHO has provided strain recommendations for seasonal" exact="influenza" post="vaccines for both egg-derived and cell-derived CVVs.25 The cell-culture"/>
  <result pre="(MDCK) cells rather than fertilized eggs. The production of cell-based" exact="influenza" post="vaccines and the cell-grown CVVs allows for the elimination"/>
  <result pre="large quantities if needed for a pandemic.25 Cell-based and recombinant" exact="influenza" post="vaccines are available for use in the United States"/>
  <result pre="viruses than egg-derived viruses.29–31 The WHO Collaborating Centre data for" exact="influenza" post="have been analyzed to determine the match of circulating"/>
  <result pre="higher proportion of the MDCK propagated viruses matched the circulating" exact="influenza" post="A/H3N2 viruses than the egg-propagated viruses.32 Other novel manufacturing"/>
  <result pre="used to isolate the HA gene from a &quot;wild type�?" exact="influenza" post="virus and then insert the HA gene in a"/>
  <result pre="the HA protein encoded by the inserted genes. The expressed" exact="influenza" post="HA protein is harvested and purified.33 The resulting HA"/>
  <result pre="host cells and this purified HA acts as the relevant" exact="influenza" post="component of the vaccine.35 The production process can produce"/>
  <result pre="5–6 weeks.34,36 Historical review of the effectiveness of egg-derived vaccines Although" exact="influenza" post="vaccines are widely recommended as influenza prophylaxis, actual effectiveness"/>
  <result pre="of egg-derived vaccines Although influenza vaccines are widely recommended as" exact="influenza" post="prophylaxis, actual effectiveness can be suboptimal. There are several"/>
  <result pre="pooled effectiveness for conventional egg-based trivalent inactivated vaccines against all" exact="influenza" post="strains over 12 seasons (between 1967 and 2011) was"/>
  <result pre="A more recent meta-analysis of test-negative design studies of egg-based" exact="influenza" post="vaccine effectiveness included 56 studies from 2004 to 2015."/>
  <result pre="respiratory illness and whose clinical samples are then tested for" exact="influenza" post="with RT-PCR. Those who test negative are used as"/>
  <result pre="older adults (24%).38 Comparative effectiveness of egg-derived and cell derived" exact="influenza" post="vaccines from the 2017–2018 season Cell-based inactivated influenza vaccines"/>
  <result pre="cell derived influenza vaccines from the 2017–2018 season Cell-based inactivated" exact="influenza" post="vaccines have been shown to be modestly more effective"/>
  <result pre="been shown to be modestly more effective than egg-based inactivated" exact="influenza" post="vaccines. A 2017–2018 real-world observational study evaluated the relative"/>
  <result pre="2017–2018 real-world observational study evaluated the relative effectiveness of inactivated" exact="influenza" post="vaccines prepared in embryonated chicken eggs compared with those"/>
  <result pre="the United States in this age group—who had received inactivated" exact="influenza" post="vaccines in a cell-based quadrivalent form (n = 659,249) or four"/>
  <result pre="evaluate the prevention of influenza-related hospital encounters. During this H3N2-dominated" exact="influenza" post="season, the IPTW-adjusted results show that for influenza-related hospital"/>
  <result pre="trivalent (RVE 1.0%, 95% −3.5 to 5.3).39 In the 2017–2018" exact="influenza" post="season, half of US service members who were immunized"/>
  <result pre="Defense Medical Surveillance System who had received either a cell-based" exact="influenza" post="vaccine or an egg-based influenza vaccine between 1 August"/>
  <result pre="had received either a cell-based influenza vaccine or an egg-based" exact="influenza" post="vaccine between 1 August 2017 and 28 April 2018."/>
  <result pre="study designs. For the case test-negative design, which included laboratory-confirmed" exact="influenza" post="cases, the adjusted RVE of cell-based influenza vaccines (n = 2467)"/>
  <result pre="which included laboratory-confirmed influenza cases, the adjusted RVE of cell-based" exact="influenza" post="vaccines (n = 2467) compared with egg-based influenza vaccines (n = 3239) was"/>
  <result pre="adjusted RVE of cell-based influenza vaccines (n = 2467) compared with egg-based" exact="influenza" post="vaccines (n = 3239) was 5% (95% CI: –10, 17). The"/>
  <result pre="or diagnosed influenza. For all cohorts, 50% received the cell-based" exact="influenza" post="vaccine. Compared with egg-based influenza vaccines, the adjusted RVE"/>
  <result pre="cohorts, 50% received the cell-based influenza vaccine. Compared with egg-based" exact="influenza" post="vaccines, the adjusted RVE of cell-based influenza vaccines for"/>
  <result pre="Compared with egg-based influenza vaccines, the adjusted RVE of cell-based" exact="influenza" post="vaccines for ILI medical encounters was 2% (95% CI:"/>
  <result pre="influenza-specific medical encounter 16% (95% CI: 11, 20), and for" exact="influenza" post="hospitalization 46% (95% CI: –18, 76). These results showed"/>
  <result pre="–18, 76). These results showed that the RVE of cell-based" exact="influenza" post="vaccines was similar to or greater than that of"/>
  <result pre="vaccines was similar to or greater than that of egg-based" exact="influenza" post="vaccines but only statistically significant for ILI and influenza-specific"/>
  <result pre="4 years of age to 64 years of age over the 2017–2018" exact="influenza" post="season.31 The study evaluated persons who received an inactivated"/>
  <result pre="influenza season.31 The study evaluated persons who received an inactivated" exact="influenza" post="vaccine that was either cell-based quadrivalent (n = 84,440) or egg-based"/>
  <result pre="were confirmed with polymerase chain reaction. The vaccine effectiveness against" exact="influenza" post="A compared with unvaccinated persons was 30.2% (95% CI:"/>
  <result pre="large United States electronic medical record dataset of the 2017–2018" exact="influenza" post="season was retrospectively evaluated to investigate the effectiveness of"/>
  <result pre="1 August 2017, to 31 March 2018, and received quadrivalent" exact="influenza" post="vaccines that were either cell-based (n = 92,192) or egg-based (n = 1,255,983)."/>
  <result pre="of ILIs was significantly higher for the cell-based quadrivalent inactivated" exact="influenza" post="vaccine compared with the egg-based vaccine 36.2% (95% CI:"/>
  <result pre="components, particularly for H3N2. All four components for the 2019–2020" exact="influenza" post="vaccine are cell-based CVV for the first time and"/>
  <result pre="outcomes for all these strains in the future.42 Conclusions Seasonal" exact="influenza" post="outbreaks and epidemics are a regular part of our"/>
  <result pre="cell-based and other nonegg technologies used for the production of" exact="influenza" post="vaccines will likely further reduce the burden of disease"/>
  <result pre="continue to search for the holy grail of a universal" exact="influenza" post="vaccine. The authors wish to thank C. Gordon Beck"/>
  <result pre="internal medicine. 20th ed.New York, NY: McGraw-Hill Education, 2018. 3SettembreECDormitzerPRRappuoliR.Bringing" exact="influenza" post="vaccines into the 21st century. Hum Vaccin Immunother2013; 10:"/>
  <result pre="21st century. Hum Vaccin Immunother2013; 10: 600–604.24378716 4BouvierNM.The future of" exact="influenza" post="vaccines: a historical and clinical perspective. Vaccines (Basel). 2018;"/>
  <result pre="Disease Control and Prevention. Estimates of deaths associated with seasonal" exact="influenza" post="— United States, 1976-2007. MMWR Morb Mortal Wkly Rep2010;"/>
  <result pre="Mortal Wkly Rep2010; 59: 1057–1062.20798667 6PebodyRWarburtonFAndrewsN, et al.Effectiveness of seasonal" exact="influenza" post="vaccine in preventing laboratory-confirmed influenza in primary care in"/>
  <result pre="6PebodyRWarburtonFAndrewsN, et al.Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed" exact="influenza" post="in primary care in the United Kingdom: 2014/15 end"/>
  <result pre="results. Euro Surveill2015; 20: pii: 30013. 7SullivanSGChilverMBCarvilleKS, et al.Low interim" exact="influenza" post="vaccine effectiveness, Australia, 1 May to 24 September 2017."/>
  <result pre="spike in excess mortality in England in winter 2014/15 –" exact="influenza" post="the likely culprit. Epidemiol Infect2018; 146: 1106–1113.29743125 9collab: Australian"/>
  <result pre="Med1987; 82: 20–25. 13GrohskopfLASokolowLZBroderKR, et al.Prevention and control of seasonal" exact="influenza" post="with vaccines: recommendations of the advisory committee on immunization"/>
  <result pre="recommendations of the advisory committee on immunization practices-United States, 2018-19" exact="influenza" post="season. MMWR Recomm Rep2018; 67: 1–20. 14WongSSWebbyRJ.Traditional and new"/>
  <result pre="influenza season. MMWR Recomm Rep2018; 67: 1–20. 14WongSSWebbyRJ.Traditional and new" exact="influenza" post="vaccines. Clin Microbiol Rev2013; 26: 476–492.23824369 15collab: Centers for"/>
  <result pre="accessed 12 December 2018). 16WeirJPGruberMF.An overview of the regulation of" exact="influenza" post="vaccines in the United States. Influenza Other Respir Viruses2016;"/>
  <result pre="Med2004; 350: 218–220.14724300 18collab: World Health Organization. Types of seasonal" exact="influenza" post="vaccine, http://www.euro.who.int/en/health-topics/communicable-diseases/influenza/vaccination/types-of-seasonal-influenza-vaccine. (2018, accessed 14 September 2018). 19ZieglerTMamahitACoxNJ.65 years"/>
  <result pre="vaccine, http://www.euro.who.int/en/health-topics/communicable-diseases/influenza/vaccination/types-of-seasonal-influenza-vaccine. (2018, accessed 14 September 2018). 19ZieglerTMamahitACoxNJ.65 years of" exact="influenza" post="surveillance by a world health organization-coordinated global network. Influenza"/>
  <result pre="global network. Influenza Other Respir Viruses2018; 12: 558–565.29727518 20Berlanda ScorzaFTsvetnitskyVDonnellyJJUniversal" exact="influenza" post="vaccines: shifting to better vaccines. Vaccine2016; 34: 2926–2933.27038130 21collab:"/>
  <result pre="34: 2926–2933.27038130 21collab: Centers for Disease Control and Prevention. How" exact="influenza" post="(flu) vaccines are made, https://www.cdc.gov/flu/protect/vaccine/how-fluvaccine-made.htm. (2018, accessed 12 September"/>
  <result pre="of vaccine, https://www.flickr.com/photos/niaid/5102830876. (2010, accessed 12 December 2018). 23HegdeNR.Cell culture-based" exact="influenza" post="vaccines: a necessary and indispensable investment for the future."/>
  <result pre="al.A structural explanation for the low effectiveness of the seasonal" exact="influenza" post="H3N2 vaccine. PLoS Pathog2017; 13: e1006682.29059230 25collab: Centers for"/>
  <result pre="BoxmeerJLeavB, et al.Retrospective evaluation of mismatch from egg-based isolation of" exact="influenza" post="strains compared to cell-based isolation and the possible implications"/>
  <result pre="27collab: Medicago. Medicago announces phase 3 study of VLP quadrivalent" exact="influenza" post="vaccine, https://media.medicago.com/webfolder_download/951cb9f9114b2ed4e132b1c563ba870f/medicago-announces-phase-3-study-of-vlp-quadrivalent-influenza-vaccine/6936dd00ddfd77a354f293f8144269ffb22c029c/medicago-announces-phase-3-study-of-vlp-quadrivalent-influenza-vaccine.pdf (2017). (accessed 14 September 2018). 28collab: Novavax."/>
  <result pre="(accessed 14 September 2018). 29LuY.Relative effectiveness of cell-cultured versus egg-based" exact="influenza" post="vaccines, 2017-18. Presented at the Advisory Committee on Immunization"/>
  <result pre="30BoikosCSylvesterGSampalisJ, et al.Effectiveness of the cell culture- and egg-derived, seasonal" exact="influenza" post="vaccine during the 2017-2018 Northern Hemisphere Influenza Season. Presented"/>
  <result pre="Canada. 31KleinNFiremanBGoddardK, et al.Vaccine effectiveness of flucelvax relative to inactivated" exact="influenza" post="vaccine during the 2017-18 influenza season in Northern California."/>
  <result pre="of flucelvax relative to inactivated influenza vaccine during the 2017-18" exact="influenza" post="season in Northern California. Presented at the IDWeek, 3–7"/>
  <result pre="October 2018, San Francisco, CA. 33DunkleLMIziksonRPatriarcaP, et al.Efficacy of recombinant" exact="influenza" post="vaccine in adults 50 years of age or older."/>
  <result pre="accessed 1 February 2019). 37OsterholmMTKelleyNSSommerA, et al.Efficacy and effectiveness of" exact="influenza" post="vaccines: a systematic review and meta-analysis. Lancet Infect Dis2012;"/>
  <result pre="and meta-analysis. Lancet Infect Dis2012; 12: 36–44.22032844 38BelongiaEASimpsonMDKingJP, et al.Variable" exact="influenza" post="vaccine effectiveness by subtype: a systematic review and meta-analysis"/>
  <result pre="16: 942–951.27061888 39IzurietaHSChillarigeYKelmanJ, et al.Relative effectiveness of cell-cultured and egg-based" exact="influenza" post="vaccines among the U.S. elderly, 2017-18. J Infect Dis2018;"/>
  <result pre="2017-18. J Infect Dis2018; 220: 1255–1264. 40CostEHuZ.Relative effectiveness of cell-based" exact="influenza" post="vaccines compared with egg-based influenza vaccines, active component U.S."/>
  <result pre="1255–1264. 40CostEHuZ.Relative effectiveness of cell-based influenza vaccines compared with egg-based" exact="influenza" post="vaccines, active component U.S. Service Members, 2017–18 Season [Poster"/>
  <result pre="41BoikosCSylvesterGSampalisJ, et al.Effectiveness of the cell culture- and egg-derived, seasonal" exact="influenza" post="vaccine during the 2017-2018 Northern Hemisphere influenza season. NFID"/>
  <result pre="and egg-derived, seasonal influenza vaccine during the 2017-2018 Northern Hemisphere" exact="influenza" post="season. NFID Clinical Vaccinology Course, 9–10 November 2018, Bethesda,"/>
 </snippets>
</snippetsTree>
